

REMARKS

Claims 8-12, 17-22 and 24-28, as amended, appear in this application for the Examiner's review and consideration. Claim 8 has been amended to recite the preferred peptides, e.g., the sequence of the CDR selected from mAb 240, mAb 246 and mAb 421, as previously recited in claim 23, which is now cancelled. Claims 24 and 25 have been amended for consistency. As no new matter is introduced by the amendments, entry of the amendments at this time is respectfully requested.


The sole rejection remaining is of claims 8-12, 17, and 18-28 under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement for the reasons set forth on pages 3-4 of the Office Action. Claim 8 is herein amended to recite that the claimed synthetic peptide is 7 to 30 amino acid residues in length of a variable region of an anti-p53 mAb and contains a sequence of the CDR is selected from mAb 240, mAb 246 and mAb 421, as previously claimed in claim 23. As the Examiner has noted that these sequences are disclosed in the specification, such as in paragraphs [0045, [0046], [0052], [0053] and [0055] and elsewhere, this rejection has been overcome and should be withdrawn.

In view of the above amendments and remarks, the entire application is believed to be in condition for allowance, early notification of such would be appreciated. Should the Examiner not agree, a personal or telephonic interview is respectfully requested to discuss any remaining issues in order to expedite the eventual allowance of the claims.

Respectfully submitted,

12/23/05

Date



Allan A. Fanucci (Reg. No. 30,256)

WINSTON & STRAWN LLP
Customer No. 28765
(212) 293-3311